BAM
CRDF icon

Belpointe Asset Management’s Cardiff Oncology CRDF Stock Holding History

Belpointe Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,778
Closed -$33.1K – 1090
2025
Q4 		$33.1K Buy
11,778
+25
+0.2% +$58 ﹤0.01% 1012
2025
Q3 		$24.2K Buy
11,753
+100
+0.9% +$276 ﹤0.01% 975
2025
Q2 		$36.7K Buy
11,653
+13
+0.1% +$40 ﹤0.01% 929
2025
Q1 		$36.5K Buy
+11,640
New +$46K ﹤0.01% 906
2023
Q2 		– Sell
-11,454
Closed -$18.9K – 1136
2023
Q1 		$18.9K Buy
11,454
+4,454
+64% +$7.65K ﹤0.01% 2335
2022
Q4 		$9.8K Buy
+7,000
New +$10K ﹤0.01% 2626

Other funds holding CRDF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return

Belpointe Asset Management's CRDF Position: Q1 2026 in Review

Belpointe Asset Management sold out of Cardiff Oncology (CRDF) in Q1 2026, closing a stake of 11,778 shares — an estimated $33.1K sold.

Belpointe Asset Management first reported a position in CRDF in Q4 2022 and held it in 6 quarters. The position peaked at $36.7K in Q2 2025. 117 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Belpointe Asset Management reported no remaining Cardiff Oncology position as of Q1 2026 after selling out during the quarter.
  • Belpointe Asset Management sold 11,778 Cardiff Oncology shares in Q1 2026, an estimated $33.1K.
  • Belpointe Asset Management first reported a position in Cardiff Oncology in Q4 2022 and held it in 6 quarters.
  • Belpointe Asset Management's Cardiff Oncology position peaked at $36.7K in Q2 2025.
  • 117 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Belpointe Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.